Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Simulation Model Based On Pooled Phase 3 Data Demonstrating Nexletol Bempedoic Acid Tablet S Potential To Lower Absolute Cardiovascular Event Risk Presented At Acc 21 is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
FDA Approval Broadens Eligibility for Treatment With Nexletol, Nexlizet
The approval was based on data from the phase 3 CLEAR Outcomes study. The Food and Drug Administration (FDA) has expanded the approval of Nexletol ® (bempedoic ... risk of having a cardiovascular ... Read More
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences. About Moderna ... Read More
Ionis to hold olezarsen Phase 3 data webcast
April 8th at 10:00 a.m. Eastern Time to discuss the olezarsen Phase 3 Balance study results in patients with familial chylomicronemia syndrome (FCS) presented at the 2024 American College of ... Read More
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
March 25, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present positive Phase 3 Balance results ... and High Cardiovascular Risk: Primary Results ... Read More
Promising Phase 3 Data on Experimental Agent Givinostat for Duchenne Muscular Dystrophy
The findings come on the eve of givinostat's March 21 US Food and Drug ... the company noted in a press release about the findings. The EPIDYS study was a phase 3, multicenter, randomized, double ... Read More
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the phase 3 ... press release may contain forward-looking statements. Forward-looking statements provide Novocure’s ... Read More
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
The focus of the event will ... global Phase 3 multi-center trial. This cardiovascular outcomes-based trial has received Special Protocol Assessment (SPA) agreement from the U.S. Food and Drug ... Read More
After Phase 3 readout, Ionis set on launching FCS agent this year
The full data, which were presented ... the U.S. At ACC, Ionis shared primary results of its Phase 2b Bridge-TIMI 73a trial in patients with sHTG at high cardiovascular risk. Olezarsen was associated ... Read More
Annovis to release efficacy data on Alzheimer's drug in April
Shares of Annovis Bio (NYSE:ANVS) jumped 10% in morning trading Wednesday following news that the company expects to have topline efficacy Phase 2/3 data in April for its drug buntanetap in the ... Read More
What's Going On With Moderna Stock Wednesday?
Moderna held its fifth Vaccines Day event ... s licensed COVID-19 vaccine mRNA-1273.222. “We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data ... Read More
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented ... are based on Moderna's current expectations and ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus